Can DIO2 rs225014 reduce tissue thyroid activation and cause low-energy symptoms despite normal serum free T4?

The type 2 deiodinase (D2) enzyme, encoded by the DIO2 gene, plays a critical role in intracellular thyroid hormone regulation by converting inactive thyroxine (T4) into the active triiodothyronine (T3) within target tissues such as the brain and skeletal muscle.

Mechanistic pathways

• Impaired enzymatic conversion: The DIO2 rs225014 (Thr92Ala) polymorphism reduces the catalytic efficiency of the D2 enzyme, limiting the local intracellular pool of active T3 available to bind nuclear thyroid hormone receptors.
• Cellular and ER stress: The Ala92-DIO2 variant accumulates abnormally in the Golgi apparatus rather than maintaining its normal endoplasmic reticulum (ER) localization. This mislocalization triggers ER stress, activates the unfolded protein response (UPR), and induces mitochondrial imbalance and cellular stress.
• Normal serum discrepancy: Because circulating thyroid hormone levels (serum free T4 and TSH) are maintained primarily by the thyroid gland and type 1 deiodinase, local tissue-level hypothyroidism can occur in carriers even when standard serum panels remain entirely normal.

Clinical implications

• Low-energy and cognitive symptoms: Skeletal muscle relies on local T3 for mitochondrial oxidative metabolism, while the brain requires it for synaptic activity. The combination of localized intracellular T3 deficiency and cellular stress in these tissues manifests clinically as persistent fatigue, decreased physical capacity, and cognitive complaints.

Bottom line

• The DIO2 rs225014 polymorphism impairs intracellular T4-to-T3 conversion and triggers ER stress, causing localized tissue hypothyroidism that drives systemic low-energy symptoms and fatigue despite entirely normal serum free T4 levels.